European Union – Medicinal products. The Court of Justice of the European Union dismissed the appeal by Teva Pharma Europe BV and another company by which they sought to have set aside the judgment of the General Court of the European Union in Teva Pharma and another company v European Medicines Agency: Case T‑140/12, in which that court had dismissed their action for annulment of the decision of the European Medicines Agency rejecting their application to place on the market the generic version of the orphan medicinal product imatinib mesylate, in so far as concerned the therapeutic indications for the treatment of chronic myeloid leukaemia.